Videos

Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.

Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

Advanced Ovarian Cancer

Platinum-Resistant Advanced Ovarian Cancer

David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.

Andre Goy, MD, discusses the agents he finds most promising for the treatment of patients with mantle cell lymphoma.

Optimal Treatment of Chemoresistant mCRC

Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.

Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.

Natalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.